Quality control of protein folding in extracellular space by Yerbury, J. J. et al.
University of Wollongong 
Research Online 
Faculty of Science - Papers (Archive) Faculty of Science, Medicine and Health 
23-7-2006 
Quality control of protein folding in extracellular space 
J. J. Yerbury 
University of Wollongong, jyerbury@uow.edu.au 
E. M. Stewart 
University of Wollongong, elises@uow.edu.au 
A. R. Wyatt 
University of Wollongong 
M. R. Wilson 
University of Wollongong, mrw@uow.edu.au 
Follow this and additional works at: https://ro.uow.edu.au/scipapers 
 Part of the Life Sciences Commons, Physical Sciences and Mathematics Commons, and the Social 
and Behavioral Sciences Commons 
Recommended Citation 
Yerbury, J. J.; Stewart, E. M.; Wyatt, A. R.; and Wilson, M. R.: Quality control of protein folding in 
extracellular space 2006. 
https://ro.uow.edu.au/scipapers/17 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Quality control of protein folding in extracellular space 
Abstract 
The pathologies of many serious human diseases are thought to develop from the effects of intra- or 
extracellular aggregates of non-native proteins. Inside cells, chaperone and protease systems regulate 
protein folding; however, little is known about any corresponding mechanisms that operate extracellularly. 
The identification of these mechanisms is important for the development of new disease therapies. This 
review briefly discusses the consequences of protein misfolding, the intracellular mechanisms that 
control folding and the potential corresponding extracellular control processes. Finally, a new speculative 
model is described, which proposes that newly discovered extracellular chaperones bind to exposed 
regions of hydrophobicity on non-native, extracellular proteins to target them for receptor-mediated 
endocytosis and intracellular, lysosomal degradation. 
Disciplines 
Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences 
Publication Details 
This article was originally published as Yerbury, JJ, Stewart, EM, Wyatt, AR and Wilson, MR, Quality control 
of protein folding in extracellular space, EMBO Reports, 6 (12), 2005, 1131-1136. Copyright Nature 
Publishing Group. Original article available here. 
This journal article is available at Research Online: https://ro.uow.edu.au/scipapers/17 
1
Quality Control of Protein Folding in Extracellular Space
Justin J. Yerbury1, Elise M. Stewart, Amy R. Wyatt and Mark R.
Wilson1,2
School of Biological Sciences, University of Wollongong, Wollongong.
NSW. 2522. Australia.
1 Corresponding authors
2 To whom pre-publication correspondence should be addressed
Total character count for manuscript (including spaces etc.): 30,570
Running Title: Quality control of extracellular protein folding




The pathologies of many serious human diseases are thought to arise from the
effects of intra- or extracellular aggregates of non-native proteins. Inside cells,
chaperone and protease systems regulate protein folding; however, little is
currently known about any corresponding mechanisms that operate
extracellularly. Identification of these mechanisms is important because this
knowledge may lead to the development of new disease therapies. This review
briefly discusses the consequences of protein misfolding, and intracellular
mechanisms that control protein folding, before examining potential
corresponding extracellular control processes. Finally, a new speculative model
is described which proposes that newly discovered extracellular chaperones bind
to exposed regions of hydrophobicity on non-native, extracellular proteins to
target them for receptor-mediated endocytosis and intracellular, lysosomal
degradation.
3
It has been estimated that about 400 grams of protein are synthesized and degraded
each day in the human body. Individual proteins are degraded at extremely varied
rates, with half-lives ranging from several minutes to many hours. Intracellularly, this
variation in half-life has been attributed to differences in the intrinsic stability of
proteins and the recognition of non-native structures by highly selective and precisely
regulated protein quality control (QC) systems.
Protein misfolding and disease
Correct protein folding is essential to provide the functional machinery for living
organisms. Mistakes in transcription or translation that result in errors as small as an
amino acid substitution can destabilize, and thus prevent, normal folding. In addition,
environmental conditions such as macromolecular crowding, inappropriate ionic
strength, oxidative stress and extremes of pH and temperature are known to promote
the (i) formation of misfolded states or slowly reacting intermediates that are trapped
on the folding pathway, and (ii) partial unfolding of fully folded native proteins.
Exposed hydrophobic regions on non-native proteins bind to similar regions on
nearby proteins by highly specific self-association (Rajan et al, 2001). The
aggregating species can continue to bind exposed hydrophobic regions of
neighbouring proteins and thus has the potential to form various stable structures,
including soluble aggregates and insoluble deposits (Fig 1). All of these protein
structures have been found associated with disease states. For example, soluble
oligomeric protein aggregates have been implicated as cytotoxic species in a variety
of neurodegenerative disorders (Demuro et al, 2005). Insoluble protein deposits
contribute to the pathology of a variety of serious human diseases (Table 1), including
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the amyloidoses that are characterized by insoluble, fibrillar protein aggregates with a
β-sheet-rich structure. 
Intracellular defences against non-native proteins
Prokaryotic and eukaryotic cells utilize post-translational QC systems, including
molecular chaperones and proteases, which are designed to repair or remove damaged
proteins.  Consequently, misfolded intracellular proteins have three possible fates:
rescue by chaperones, destruction by proteases, or aggregation. Chaperones are a
diverse group of proteins that selectively recognize and bind exposed hydrophobic
surfaces of non-native proteins in a stable non-covalent interaction. Several families
of chaperones, defined by size, cellular compartment and function, work together to
prevent protein aggregation and facilitate the correct folding of non-native proteins.
By regulated binding and release, chaperones may directly facilitate the folding of
proteins by a mechanism that is ATP-dependent (for example, heat shock protein 90
(Hsp90), Hsp70, and Hsp60 in the cytosol) or independent (for example, calnexin and
calreticulin in the endoplasmic reticulum) (Fink, 1999; Hartl & Hayer-Hartl, 2002).
Other types of chaperones (for example, the small heat shock protein Hsp25 and α-
crystallin) bind reversibly to exposed hydrophobic regions on unfolded polypeptides
but are generally unable to independently facilitate refolding. They are thought to
protect non-native proteins from aggregation until "folding-helper" chaperones are
available (Bross et al, 1999).
Misfolded proteins may be degraded by a variety of proteases in different cell
compartments, however, the major intracellular site of degradation is the proteasome,
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a barrel-shaped cytosolic protein complex that selectively degrades proteins tagged
with ubiquitin (Hohfeld et al, 2001). Polyubiquitin chains are attached to misfolded
proteins by ubiquitin ligases and cofactors in the cytosol (Welchman et al, 2005);
ubiquitination is also known to occur in the ER lumen (Tsai et al, 2002). Proteins
destined for secretion into the extracellular environment undergo a rigorous QC
process within the ER lumen, which includes interaction with a battery of ER-resident
chaperones. Some of the ER chaperones, such as calnexin and calreticulin, are lectins
that have a specialized role in the QC of glycoprotein folding. Many QC substrates
cycle between the ER and the Golgi during their maturation (Trombetta & Parodi,
2003). When misfolded proteins originally destined for secretion cannot be refolded,
they are usually either degraded by ER proteinases, directed to the lysosome or, more
commonly, retro-translocated into the cytosol for proteasomal degradation (Fig 2).
Under circumstances when the chaperone/protease machinery is overwhelmed,
misfolded proteins may form insoluble aggregates inside the ER (Trombetta &
Parodi, 2003) or in the cytosol (an aggresome). Once proteins are secreted, they
escape characterised intracellular QC processes and enter an environment in which
the mechanisms of folding control (if they exist) have yet to be discovered.
Are extracellular proteins subject to quality control?
There is, on average, 15 litres of extracellular fluids in a 70 kg human, including five
litres of blood. Compared with intracellular fluid, extracellular fluids have a lower
protein concentration (6% in plasma and 2% in interstitial fluid, 30% in cytosol) but
are more oxidizing (Sitia & Braakman, 2003).  Unlike intracellular fluids,
extracellular fluids are continuously subjected to shear stress (for example, the
pumping of plasma around the body) which is known to induce protein unfolding and
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aggregation (Ker & Chen, 1998). Intuitively, the relatively harsh extracellular
conditions suggest that active protein QC mechanisms are required. Studies from past
decades provide substantive support for this hypothesis. For example, in the 1970’s
and 80's it was shown that denatured plasma proteins were catabolized in vivo more
rapidly than their native counterparts (Margineanu & Ghetie, 1981) and that the
catabolic rates of plasma proteins correlate with their in vitro susceptibility to
proteases (Dice & Goldberg, 1976). In addition, liposomes with greater surface-
exposed hydrophobicity were cleared from circulation more quickly than those coated
with a hydrophilic polymer; it was proposed that clearance was enhanced by plasma
factors that could bind to exposed hydrophobic surfaces on the liposomes (Senior et
al, 1991). These data are consistent with the hypothesis that, as occurs intracellularly,
exposed hydrophobicity may be the structural change that identifies individual
extracellular proteins as needing QC intervention. Further support for this hypothesis
comes from the demonstration that a recently discovered extracellular chaperone,
clusterin (see below), binds to its substrates by hydrophobic interactions (Poon et al,
2002).
What protein QC mechanism(s) actually operate in extracellular space? Substantial
recent advances in understanding intracellular protein QC mechanisms highlight our
near-complete lack of understanding of corresponding extracellular processes. While
not excluding other possibilities, the potential involvement of chaperones and
selective protease systems are clearly worth considering.
Extracellular chaperones and proteasome-like systems
Intracellular folding-helper chaperones (for example, Hsp70 & Hsp90) may be
released from necrotic cells or during viral cell lysis; they have been discovered in
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human plasma and associated with cell surfaces, in particular cancer cells. Numerous
extracellular roles have been postulated for these chaperones, such as cancer cell
invasiveness (Eustace et al, 2004) and immune presentation (Becker et al, 2002). If
established, these specialized functions are clearly important. However, in the context
of generic mechanisms for extracellular protein QC, it is pertinent to note that these
"normally intracellular" chaperones are present extracellularly at very low (ng/ml)
levels and require ATP to effect protein refolding. The abundance of extracellular
ATP is at least 1000 times lower than inside cells (Farias et al, 2005). In the event of
a large-scale presentation of extracellular non-native protein(s), such as might occur
during a chronic infection, the capacity of the low levels of Hsp70 and similar
chaperones present extracellularly would be quickly exceeded. Thus, although a role
for these chaperones in extracellular protein QC cannot be excluded, it is far more
likely that large-scale "handling" of non-native proteins is dealt with by much more
abundant extracellular chaperones (ECs).  Two such ECs have recently been
identified.
Clusterin, a ubiquitous and highly conserved secreted protein, is an efficient EC
(Humphreys et al, 1999; Wilson & Easterbrook-Smith, 2000). Clusterin potently
inhibits stress-induced protein aggregation by ATP-independent binding to non-native
proteins to form soluble, high molecular weight complexes (Humphreys et al, 1999;
Poon et al, 2000). More recently, it was established that haptoglobin (Hp; previously
best known for its high-affinity binding to haemoglobin) is also an abundant EC with
a chaperone action similar to clusterin (Yerbury et al, 2005). Both ECs are highly
conserved, widely distributed glycoproteins that are present in most physiological
fluids, including plasma and cerebrospinal fluid (Bowman & Kurosky, 1982; Jenne &
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Tschopp, 1992). They are composed of variably sized oligomers made up of different
numbers of disulfide-linked α and β subunits, bind to a broad range of ligands, and
have been detected in association with clinical amyloid deposits in vivo (Calero et al,
2000; Powers et al, 1981). In human plasma, clusterin is present at about 100 µg/ml
(Humphreys et al, 1999) and Hp at 0.3-1.9 mg/ml (Bowman & Kurosky, 1982).
Immunoaffinity depletion of either clusterin or Hp from human serum renders
proteins in whole serum more susceptible to aggregation and precipitation (Poon et al,
2000; Yerbury et al, 2005).
Neither clusterin nor Hp has the ability to independently refold heat-stressed, non-
native enzymes (Poon et al, 2000; Yerbury et al, 2005). However, like the small heat
shock proteins, clusterin is able to preserve heat-inactivated enzymes in a state
competent for subsequent ATP-dependent refolding by Hsc70 (Poon et al, 2000).
Although it is possible that specifically extracellular folding-helper chaperones exist,
they remain to be convincingly demonstrated. It was reported that the plasma
pentraxin serum amyloid P component (SAP) had some ATP-independent refolding
activity in vitro. Currently, the physiological relevance of this is uncertain because, to
effect significant refolding, SAP was required at a 10-fold molar excess to the only
substrate tested (lactate dehydrogenase) (Coker et al, 2000). Further studies of the
chaperone action of SAP, using other substrates, and investigation of potential
interactions between SAP and other ECs would be enlightening. SAP is a major
plasma acute phase protein in mice but this role is played in humans by the related
pentraxin C-reactive protein (CRP) (Mold et al, 2001); it is tempting to speculate that
CRP may also be an EC. It is likely that other abundant ECs will be discovered in the
future.
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Previous studies have indicated that 50-90% of plasma proteins are degraded in the
liver and reticuloendothelial system (Bouma, 1982). This suggests that a major
component of any extracellular protein QC system comprises mechanism(s) for
cellular uptake and intracellular degradation of aged/non-native proteins. However,
this does not exclude the existence of selective mechanism(s) for the proteolysis of
extracellular non-native proteins. Both ubiquitin and the proteasome are found in
human plasma and their concentrations increase during disease, possibly reflecting
their release from dead and dying cells. The plasma concentrations reported range
from 7.7-200 ng/ml (Akarsu et al, 2001; Savas et al, 2003) and 2.1-2.4 µg/ml
(Lavabre-Bertrand et al, 2001; Stoebner et al, 2005), respectively. At these levels,
ubiquitin and the proteasome are probably at least 300 times less abundant in human
plasma than inside cells (Born et al, 1996; Lightcap et al, 2000). In addition,
extracellular proteasome-mediated protein degradation would require extracellular
ATP which, as noted above, is scarce. Therefore, current evidence does not support a
major role for the mammalian ubiquitin/proteasome system in extracellular protein
QC. Nevertheless, the existence of other extracellular protease systems that might
perform a similar function, perhaps independently of ATP, remains a possibility.
A control mechanism for extracellular protein folding
There are four, not mutually exclusive, theoretical models for extracellular QC. Non-
native extracellular proteins may be:
(1)  Assisted to refold in the extracellular space. As discussed above, there is currently
no evidence to substantiate this.
(2)  Selectively endocytosed via receptors and degraded intracellularly. This appears
feasible and will be discussed in more detail below.
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(3)  Randomly endocytosed and selected at the level of (for example) sorting
endosomes, for degradation, while recycling native extracellular proteins back to the
extracellular space. This model cannot be excluded but currently there is no evidence
to support it.
(4)  Randomly endocytosed and non-selectively degraded intracellularly. This model
can be excluded because it cannot account for the more rapid catabolism of denatured
versus native plasma proteins observed in vivo (described above).
While not excluding models (1) or (3), by providing a framework for how it might
work in practice, recent advances support model (2) . If a QC mechanism "senses"
increased hydrophobicity on non-native proteins to select them for "processing",
obvious candidates for the sensing role are the recently identified ECs clusterin and
Hp. Other yet to be identified ECs may also be involved. The formation of non-
covalent complexes between ECs and non-native extracellular proteins would
effectively label the latter for QC processing. The suggestion that ECs complex with
misfolded proteins in vivo is strongly supported by (i) in vitro, ECs inhibit the
aggregation of purified proteins subjected to chemical and physical stresses by
forming stable non-covalent complexes with them (Humphreys et al, 1999; Yerbury
et al, 2005), and (ii) the same (endogenous) ECs in unfractionated human serum
inhibit heat-induced aggregation of serum proteins (Poon et al, 2000; Yerbury et al,
2005). It will be important to experimentally verify the formation of complexes
between ECs and non-native proteins in vivo. There are precedents for the idea that by
complexing with proteins, ECs can mediate uptake of their protein ligands via cell
surface receptors and direct them towards intracellular degradation. For example,
complexes formed in vivo between clusterin and Alzheimer's beta peptide (Aβ) are
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taken up by neural epithelial cells via megalin (LRP2)-mediated endocytosis and
degraded in lysosomes (Hammad et al, 1997).  Furthermore, Hp-haemoglobin
complexes are quickly bound and internalized by CD163 expressed on human
macrophages and are subsequently degraded (Kristiansen et al, 2001). We propose
that by virtue of their interactions with both extracellular non-native proteins and cell
surface receptors, ECs identify and deliver non-native proteins for cell uptake and
degradation (Fig 3).
If this model is correct, then it would be expected that manipulation of EC expression
might affect the clearance and/or aggregation of proteins in animal models. Recent
work with clusterin "knock-out" (KO) mice supports the hypothesis that clusterin
exerts important effects on protein clearance and aggregation in vivo. For example, a
long-term study of clusterin KO mice showed that aging mice developed a
progressive glomerulopathy characterized by the accumulation of insoluble protein
(containing immunoglobulins) in the kidney mesangium (Rosenberg et al, 2002).
Another study of double KO mice with ablated expression of both clusterin and
apolipoprotein E genes concluded that these two proteins worked together to inhibit
the deposition of fibrillar Aβ in a model for Alzheimer's disease (DeMattos et al,
2004). Published studies of Hp KO mice have not examined the effects of Hp on the
aggregation/clearance of non-native extracellular proteins; it is however interesting to
note that ablation of Hp expression caused a small but significant reduction in post-
natal viability (Lim et al, 1998).
The literature reveals a number of cell surface molecules that might be involved in
receptor-mediated endocytosis of EC-(non-native)protein complexes. For example,
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clusterin interacts with several members of the low density lipoprotein (LDL) receptor
family. Clusterin binds to chicken LR8 and an LDLR-related protein (Mahon et al,
1999), and uptake of clusterin-leptin complexes by apoER2 and VLDLR  has been
proposed to facilitate leptin clearance (Bajari et al, 2003). Furthermore, clusterin and
LRP1/megalin have been implicated in the clearance of cellular debris by non-
professional phagocytes (Bartl et al, 2001). Aside from CD163, another potential
candidate receptor for Hp-(non-native)protein complexes is the CD11b/CD18 integrin
(Mac-1/CR3), which binds to Hp, denatured proteins and the iC3b fragment of
complement (Ross, 2000). SAP, and C-reactive protein, are also known to bind and be
internalized by Fc receptors (Mold et al, 2001). These observations provide leads to
pursue in future studies of extracellular protein QC.
Concluding remarks
If the hypothesis is correct that a QC system exists to oversee the folding of
extracellular proteins, then it follows that dysfunctions of this system may contribute
to the development of diseases associated with inappropriate extracellular protein
aggregation and deposition. Therefore, elucidation of the mechanisms controlling
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Figure Legends
Figure 1  Schematic diagram of pathways of protein aggregation. For each
protein, there is thought to be an ensemble of possible structures: native (N) and non-
native (NN), the latter including partly unfolded intermediates (I1 and I2) and unfolded
(U) structures.  The non-native structures are prone to associate with each other to
form aggregates, although native proteins may sometimes also aggregate to form
fibres. Non-fibrillar (amorphous) aggregates result from non-specific interactions
between many different conformations, whereas highly structured amyloid fibrils can
be formed by β-sheet-rich intermediates. Soluble structures are shown in the internal
white rectangle, insoluble structures in the outer yellow region.
Figure 2  Outline of major intracellular controls of protein folding. In the cytosol,
non-native proteins are recognized by chaperones and are targeted for refolding or
proteolytic degradation by the proteasome or lysosome (Hohfeld et al, 2001). In the
endoplasmic reticulum (ER), newly synthesized proteins or other non-native proteins
are assisted to fold by chaperones. ER-Golgi cycling may occur at this stage. If a
native conformation is achieved, the protein may be secreted from the cell.  If a non-
native conformation persists, it can be proteolytically degraded either within the ER,
by the proteasome following retro-translocation into the cytosol, or following
transport to the lysosome (Trombetta & Parodi, 2003). Under some circumstances,
aggregated non-native proteins can accumulate as insoluble deposits inside the ER or
in the cytosol as an aggresome. For simplicity, cofactors involved in many of these
processes are not shown. See key for other details.
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Figure 3  Speculative model for extracellular chaperone-mediated clearance of
non-native proteins. Non-native extracellular proteins are bound by extracellular
chaperones that mediate their uptake into cells by receptor-mediated endocytosis.
EC-NN complexes are internalized and moved by vesicular transport to lysosomes,
where they are degraded. Receptors are recycled back to the cell surface (not shown).
The primary sites of action of this process are likely to be the liver and the
reticuloendothelial system. See key for other details.
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Table 1 Proteins forming insoluble deposits associated with disease
Protein involved Disease(s)              Deposit structure
Amyloid–β * Alzheimer’s disease F, A
Tau Alzheimer’s disease F
α-Synuclein Parkinson’s disease, Lewy body dementia F, A
Amylin* Diabetes type 2 F, A
SOD1 Amyotrophic Lateral Sclerosis F
β2-Microglobulin * Haemodialysis-related amyloidosis F, A
Amyloid-A * Reactive amyloidosis F, A
Haemoglobin Sickle cell anaemia F
Huntingtin Huntington’s disease F
PrP * Creutzfeldt-Jakob disease F, A
Androgen receptor Spinobulbar muscular atrophy F
Ataxins 1, 2 & 3 Spinocerebellar ataxia’s 1, 2 & 3 F
IgG * Non-amyloid monoclonal IgG deposition disease NF
Kerato-epithelin * Certain corneal dystrophies NF
Ten other proteins* Systemic and cerebral hereditary amyloidosis F, A
* indicates the protein is deposited extracellularly. F = fibrillar, A = amyloid, NF =
non-fibrillar
Data sourced from (Korvatska et al, 1999; Lin et al, 2001; Sherman & Goldberg,
2001; Soto, 2001)



